In the News

Eisai Co. and Wren Therapeutics Collaborate to Target Alpha-Synuclein

By December 8, 2020 December 16th, 2020 No Comments

Eisai Co. and Wren Therapeutics Collaborate to Target Alpha-Synuclein  

The two companies announced an exclusive collaboration agreement that aims to develop treatments that target alpha-synuclein, a protein whose accumulation in the brain causes several neurodegenerative disorders, such as Parkinson’s disease and dementia with Lewy bodies. There is currently a large unmet need for treatments for these debilitating diseases. 

 In the future, the Syn-One Test™ may aid in identifying the right patients for alpha-synuclein-targeting therapies and could then be used to monitor the effectiveness of these treatments on an individual patient level. 

 

READ MORE
CND Life Sciences

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.